Amerikanische Gesellschaft für Hirudotherapie

The type II secretion system is essential for erythrocyte lysis and gut colonization by the leech digestive tract symbiont Aeromonas veronii

Basic science / microbiology published in Appl Environ Microbiol (2011)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Sicherheit & InfektionskontrolleGenomik & ProteomikMaltz M et al. · Applied and environmental microbiology, 2011

Abstract

Hemolysin and the type II secretion system (T2SS) have been shown to be important for virulence in many pathogens, but very few studies have shown their importance in beneficial microbes. Here, we investigated the importance of the type II secretion pathway in the beneficial digestive-tract association of Aeromonas veronii and the medicinal leech Hirudo verbana and revealed a critical role for the hemolysis of erythrocytes. A mutant with a miniTn5 insertion in exeM, which is involved in forming the inner membrane platform in the T2SS, was isolated by screening mutants for loss of hemolysis on blood agar plates. A hemolysis assay was used to quantify the mutant's deficiency in lysing sheep erythrocytes and revealed a 99.9% decrease compared to the parent strain. The importance of the T2SS in the colonization of the symbiotic host was assessed. Colonization assays revealed that the T2SS is critical for initial colonization of the leech gut. The defect was tied to the loss of hemolysin production by performing a colonization assay with blood containing lysed erythrocytes. This restored the colonization defect in the mutant. Complementation of the mutant using the promoter region and exeMN revealed that the T2SS is responsible for secreting hemolysin into the extracellular space and that both the T2SS and hemolysin export by the T2SS are critical for initial establishment of A. veronii in the leech gut.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, Non-P.H.S.
Indexed MeSH termsAeromonasAnimalsBacterial ProteinsDNA Transposable ElementsDNA, BacterialErythrocytesGastrointestinal TractHemolysisLeechesMembrane Transport ProteinsMolecular Sequence DataMutagenesis, Insertional

Zusammenfassung

Mutagenesis study identifying the type II secretion system (T2SS) and hemolysin export as critical for erythrocyte lysis and gut colonization of medicinal leeches by Aeromonas veronii. exeM mutants showed 99.9% reduction in hemolysis.

Warum dies für die Hirudotherapie relevant ist

This study investigated the role of the type II secretion system (T2SS) in the beneficial digestive-tract association of Aeromonas veronii with the medicinal leech Hirudo verbana. A mutant with a disrupted T2SS component (exeM) showed a 99.9% reduction in hemolysis of sheep erythrocytes and a colonization defect in the leech gut; this defect was rescued when the mutant was fed blood containing pre-lysed erythrocytes. Complementation with exeMN restored hemolysin secretion and colonization, confirming that T2SS-mediated hemolysin export is critical for initial establishment of A. veronii in the leech gut. For ASH's domain, this contributes to understanding the digestive-tract biology of the medicinal leech and its symbiotic associations. The caveat is that this is a basic microbiology study in a leech model with no direct hirudotherapy, secretome, or clinical application, and it does not address leech therapy outcomes.

Zitation

The type II secretion system is essential for erythrocyte lysis and gut colonization by the leech digestive tract symbiont Aeromonas veronii.

Maltz M et al. · Applied and environmental microbiology, 2011

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.